Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Arovella Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
Health Check: Percheron ‘closes the book’ on failed childhood rare disease program
Health & Biotech
Health Check: Radiopharm dials up after gaining new major shareholder
Health & Biotech
Dr Boreham’s Crucible: This cancer-tackling biotech might just have a fighting chance
Health & Biotech
Health Check: No sign of frayed nerves as Orthocell girds for US approval
Health & Biotech
ASX Health Stocks: LBT skyrockets 40pc after winning deal with global pharma, AstraZeneca
Health & Biotech
Weed Week: MDMA for PTSD hits roadblock with FDA; and recent ASX cannabis stock winners
Health & Biotech
Top ASX biotechs catching the eye of analysts and fund managers in 2024 – Part 1
Health & Biotech
ASX Health Winners March: A rebound? Aussie biotech sector is on the radar of Asian investors
News
Closing Bell: ASX loses its bottle, but Gold50 shows some Gallium to advance 50pc
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
Weed Week: Cannabis can ‘kill melanoma’; and Germany legalises weed possession
Health & Biotech
Weed Week: Iron Mike throws down challenge to Biden, and recent ASX pot winners
Health & Biotech
Fundie Merchant Group picks four biotech stocks that could rip as sector hits rude health again
Health & Biotech
ASX Health Winners January: ‘Invest in business not science’, as SHG and PAA top winners list
Health & Biotech
ASX Health Stocks: A breakthrough for CAR T therapy? Arovella signs deal to advance CAR-iNKT platform
News
Rise and Shine: Everything you need to know before the ASX opens
News